Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Dowlais profits, revenues hit by ePowertrain weakness

(Sharecast News) - Dowlais reported a drop in full-year profit and revenue on Wednesday, citing significant headwinds faced by its ePowertrain product line. In the year to the end of December 2024, adjusted pre-tax profit fell to £215m from £264m a year earlier, with revenue down 6.4% at £4.9bn.

Dowlais said that about 70% of this revenue decline was driven by weakness in the ePowertrain product line, due to ongoing volatility in battery electric vehicles (BEV) production schedules.

Adjusted operating profit fell 4.2% to £324 million, Dowlais said. This included £9m of operating losses from Hydrogen operations, driven primarily by lower volumes.

Chief executive Liam Butterworth said: "In 2024, strong execution enabled us to navigate a challenging environment and deliver on our updated guidance. Our market-leading Driveline business slightly outperformed the market outside of China, whereas our ePowertrain product line faced significant headwinds due to ongoing volatility in BEV production schedules, contributing to the majority of the group's 6.4% adjusted revenue decline year-on-year.

"Proactive cost management and commercial recoveries enabled us to improve our adjusted operating margin by 10bps, demonstrating our disciplined approach to protecting margins."

Dowlais - which was formed from the demerger of Melrose Industries' GKN Automotive, GKN Powder Metallurgy and GKN Hydrogen businesses - announced in January that it had agreed to be taken over by American Axle & Manufacturing in a £1.16bn deal.

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.